research Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
Search
for
Sort by
Research
750-780 / 1000+ results 
research Frontal Fibrosing Alopecia
Frontal Fibrosing Alopecia is a hair loss condition mainly affecting postmenopausal women, with unclear causes and various clinical patterns.
research FUE Hair Transplantation
FUE is a minimally invasive hair transplant method using various donor sites.
research Frontal fibrosing alopecia presenting with rapidly spreading facial papules in a premenopausal woman: Case report and review
A young woman developed facial bumps before hair loss, which is unusual for her condition.
research Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study
Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
research The most impactful aspects of living with alopecia areata among patients commencing systemic treatments: Evaluating patients’ perspectives to guide therapy
Facial hair loss and psychosocial issues are crucial in deciding treatment for alopecia areata.
research Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
research Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is effective long-term for treating alopecia areata in teens.
research Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
research Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute
Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
research Baricitinib regrows hair in adolescents with alopecia areata
Baricitinib helps regrow hair in teens with severe alopecia areata.
research Race and Ethnicity Sub-Groups of Alopecia Areata Patients have Differing Clinical Characteristics: TARGET-DERM AA
Alopecia areata severity and symptoms vary by race and ethnicity.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research Depression among Alopecia Areata Patients: Prevalence and associated factors in a Tunisian sample
Over half of alopecia areata patients in Tunisia experience depression, highlighting the need for psychological support.
research 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
research 50524 Facebook groups provide support and product recommendations for patients using scalp cooling to prevent chemotherapy-induced alopecia: A survey study
Facebook groups play a crucial role in supporting and guiding patients on scalp cooling and hair loss during chemotherapy.
research Efficacy of modern methods for assessing the severity of alopecia areata
The SBN system effectively assesses alopecia areata severity and predicts its course.
research 131 Patient experiences with alopecia areata: Sentiment analysis of survey responses
Alopecia areata causes negative emotions and stress due to hair loss and emotional triggers.
research Ciliary Madarosis Secondary to Intra-Arterial Chemotherapy for Retinoblastoma Treatment
Eyelash loss can temporarily occur from chemotherapy for retinoblastoma.
research Ayurvedic Management of Pakshmashata (Madarosis): A Case Report
Ayurvedic treatment helped a woman regrow her lost eyebrow and eyelash hair.
research Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2
Baricitinib effectively treats severe alopecia for up to 104 weeks.
research Clouston Syndrome: Report of a Jordanian Family with GJB6 Gene Mutation
A Jordanian family with Clouston syndrome has a common GJB6 gene mutation.
research BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.
research Madarosis and facial keratinaceous spines
Reducing immunosuppression and using antiviral creams improved the woman's skin condition.
research Micropigmentation
Micropigmentation is a cosmetic tattooing technique for hiding skin issues and creating permanent makeup, but it can have side effects.
research Unilateral Ciliary Madarosis in a Child After Coronavirus Disease 2019 (COVID-19) Infection
A child lost eyelashes on one eyelid after COVID-19, likely due to a temporary hair loss condition.
research Signposts to the Promised Land in Alopecia Areata
Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.
research 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
research A qualitative phase I study protocol on developing patient-reported outcome measure for hair, scalp, eyebrows, eyelashes, and beard-related skin disorders
The goal is to create a tool for patients to report their experiences with various hair and scalp disorders.
research An eruption of numerous spiny papules in a pediatric transplant patient
Early recognition and treatment of VATS in transplant patients improve outcomes.